Cytosorbents Corp logo

CTSO

Cytosorbents Corp

$1.84

Earnings Summary

Revenue
$8.5Mn
Net Profits
$-10.88Mn
Net Profit Margins
-128.05%

Highlights

Revenue:

Cytosorbents Corp’s revenue fell -29.34% since last year same period to $8.5Mn in the Q2 2022. On a quarterly growth basis, Cytosorbents Corp has generated 7.21% jump in its revenue since last 3-months.

Net Profits:

Cytosorbents Corp’s net profit fell -132.58% since last year same period to $-10.88Mn in the Q2 2022. On a quarterly growth basis, Cytosorbents Corp has generated -21.33% fall in its net profits since last 3-months.

Net Profit Margins:

Cytosorbents Corp’s net profit margin fell -229.16% since last year same period to -128.05% in the Q2 2022. On a quarterly growth basis, Cytosorbents Corp has generated -13.17% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Cytosorbents Corp post its latest quarter earnings

EPS Estimate Current Quarter
-0.13
EPS Estimate Current Year
-0.13

Highlights

EPS Estimate Current Quarter:

Cytosorbents Corp’s earning per share (EPS) estimates for the current quarter stand at -0.13 - a -8.33% fall from last quarter’s estimates.

EPS Estimate Current Year:

Cytosorbents Corp’s earning per share (EPS) estimates for the current year stand at -0.13.

Key Ratios

Key ratios of the Cytosorbents Corp post its Q2 2022 earnings

Earning Per Share (EPS)
-0.25
Return on Assets (ROA)
-0.22
Return on Equity (ROE)
-0.58
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Cytosorbents Corp’s earning per share (EPS) fell -127.27% since last year same period to -0.25 in the Q2 2022. This indicates that the Cytosorbents Corp has generated -127.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cytosorbents Corp’s return on assets (ROA) stands at -0.22.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cytosorbents Corp’s return on equity (ROE) stands at -0.58.

Dividend Per Share (DPS):

Cytosorbents Corp declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-03
-0.12
-0.21
-75%
2022-08-02
-0.13
-0.25
-92.31%

Company Information

CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 66 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. CytoSorb® has been used in more than 110,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $38 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple applications pending, including ECOS-300CY™, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.

Organisation
Cytosorbents Corp
Headquarters
Monmouth Junction, New Jersey, US
Employees
195
Industry
Health Technology
CEO
Phillip Chan